ALLR Allarity Therapeutics, Inc.

Nasdaq allarity.com


$ 1.51 $ -0.08 (-4.97 %)    

Monday, 13-Oct-2025 19:38:00 EDT
QQQ $ 601.81 $ 12.51 (2.12 %)
DIA $ 460.92 $ 5.81 (1.28 %)
SPY $ 662.71 $ 10.02 (1.53 %)
TLT $ 90.54 $ -0.05 (-0.06 %)
GLD $ 379.71 $ 8.97 (2.43 %)
$ 1.53
$ 1.77
$ 1.50 x 115
$ 1.80 x 72
$ 1.53 - $ 1.77
$ 0.61 - $ 2.35
427,180
na
22.37M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-15-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 10-07-2022 06-30-2022 10-Q
14 05-27-2022 03-31-2022 10-Q
15 05-16-2022 09-30-2021 10-Q
16 05-16-2022 12-31-2021 10-K
17 11-23-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-maintains-buy-on-allarity-therapeutics-raises-price-target-to-925

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target ...

 reported-earlier-allarity-therapeutics-enters-into-a-securities-purchase-agreement--secures-25m

-SEC Filing

 stock-market-today-nasdaq-100-futures-slip-palo-alto-xp-allarity-earnings-in-focus-updated

U.S. stock futures slipped on Monday following Friday's mixed moves. Futures of major benchmark indices were lower.

 allarity-therapeutics-q2-eps-015-beats-021-estimate

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of...

 ascendiant-capital-initiates-coverage-on-allarity-therapeutics-with-buy-rating-announces-price-target-of-9

Ascendiant Capital analyst Edward Woo initiates coverage on Allarity Therapeutics (NASDAQ:ALLR) with a Buy rating and announ...

 allarity-therapeutics-patent-application-for-drp-companion-diagnostic-for-stenoparib-accepted-by-ip-australia

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutica...

 allarity-therapeutics-files-form-rw-has-determined-not-to-pursue-the-public-offering-to-which-the-registration-statement-relates-the-registration-statement-has-not-been-declared-effective-by-the-commission-and-no-securities-have-been-issued-or-sold-under-the-registration-statement

https://www.sec.gov/Archives/edgar/data/1860657/000121390025056913/ea024655701-rw_allaritythera.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION